Entresto for chronic heart failure with preserved ejection fraction

featured image
Indications: Heart failure (HF)
Therapeutic Areas: Cardiovascular System
Year: 2019

Entresto (a tablet comprising a combination of the drugs sacubitril and valsartan), is in clinical development for people with chronic heart failure with preserved ejection fraction. Heart Failure (HF) is a complex clinical syndrome of symptoms and signs that suggest the efficiency of the heart as a pump is impaired. Symptoms include breathlessness and fatigue, and signs of the condition include swollen ankles and crackling sounds in the lungs. People with HF often have a poor quality of life, and about a third of people experience severe and prolonged depressive illness. About half of people with HF have a preserved ejection fraction (HF-PEF), meaning that over 50% of the blood in the left ventricle is pumped out with each contraction of the heart.
Entresto is licensed in the UK for treating people with HF with a reduced ejection fraction. The drug combination works by augmenting the actions of natriuretic peptides, which defend the heart from volume and pressure overload. Trials have shown that treatment with Entresto can reduce pressure and wall stress in the left ventricle. If licensed, Entresto could provide a treatment for people with HF-PEF, who currently have no effective treatments available.